• NovaBay published its annual report on Form 10-K, reporting a net loss of USD 22.14 million and a net loss from continuing operations of USD 33.22 million.
• General and administrative expense rose 3% to USD 7.59 million, which management attributed mainly to higher legal costs tied to non-recurring strategic initiatives.
• Total operating expenses increased 14% to USD 8.44 million, including an impairment of long-lived assets of USD 0.85 million related primarily to excess leased office capacity following the company’s strategic realignment.
• A non-cash loss on changes in the fair value of warrant liabilities was USD 24.49 million, compared with a non-cash gain in the prior year.
• Management said cash and cash equivalents were USD 8.00 million at year-end and expects existing liquidity, plus financing completed after year-end, to fund planned operating expenses at least through March 19, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBay Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-009090), on March 19, 2026, and is solely responsible for the information contained therein.